Overview Dividends

(ISRG) Intuitive Surgical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46120E6023

Robotic, Surgical, System, Instruments, Diagnostic

ISRG EPS (Earnings per Share)

EPS Growth (3Y CAGR): -54.90%
EPS Trend (3Y Correlation): -10.1%

ISRG Revenue

Revenue Growth (3Y CAGR): 17.73%
Revenue Trend (3Y Correlation): 96.8%

Description: ISRG Intuitive Surgical

Intuitive Surgical (NASDAQ: ISRG) designs, manufactures, and markets robotic and endoluminal platforms that enable minimally invasive procedures. Its flagship da Vinci Surgical System delivers multi-port robotic assistance for a broad range of operations, while the newer Ion endoluminal system expands the portfolio into bronchoscopic lung biopsies, positioning the firm across both therapeutic and diagnostic spaces.

In FY 2023 the company generated approximately $5.6 billion in revenue, with the da Vinci system accounting for roughly 85 % of sales and the Ion platform contributing a rapidly growing share as hospitals adopt minimally invasive diagnostics. Operating margins have hovered near 30 % due to high-margin consumables (staplers, energy instruments) and recurring service contracts that provide a stable cash-flow base. The firm’s direct-sales model-comprising capital and clinical teams-supports high adoption rates, but also concentrates revenue exposure to hospital capital-budget cycles.

Key economic drivers include rising global healthcare spending, an aging population that increases demand for less invasive surgeries, and a projected 10 % CAGR for the worldwide robotic surgery market through 2028. A sector-specific risk is the potential for competitive entry from emerging robotic platforms, which could compress pricing or shift market share if they achieve comparable clinical outcomes.

For a deeper, data-driven assessment of ISRG’s valuation and risk profile, the ValueRay platform offers a granular, model-backed view worth exploring.

ISRG Stock Overview

Market Cap in USD	159,927m
Sub-Industry	Health Care Equipment
IPO / Inception	2000-06-13

ISRG Stock Ratings

Growth Rating	31.0%
Fundamental	71.0%
Dividend Rating	-
Return 12m vs S&P 500	-25.4%
Analyst Rating	4.03 of 5

ISRG Dividends

Currently no dividends paid

ISRG Growth Ratios

Growth Correlation 3m	-88.8%
Growth Correlation 12m	-59.7%
Growth Correlation 5y	73.6%
CAGR 5y	27.15%
CAGR/Max DD 3y (Calmar Ratio)	0.92
CAGR/Mean DD 3y (Pain Ratio)	3.20
Sharpe Ratio 12m	0.61
Alpha	-29.95
Beta	1.611
Volatility	31.52%
Current Volume	2209.2k
Average Volume 20d	2197.7k
Stop Loss	432.3 (-3.1%)
Signal	0.55

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (2.61b TTM) > 0 and > 6% of Revenue (6% = 548.7m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 7.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 77.13% (prev 81.44%; Δ -4.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 2.83b > Net Income 2.61b (YES >=105%, WARN >=100%)

Net Debt (-3.40b) to EBITDA (3.26b) ratio: -1.04 <= 3.0 (WARN <= 3.5)

Current Ratio 5.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (364.1m) change vs 12m ago 0.86% (target <= -2.0% for YES)

Gross Margin 66.65% (prev 66.86%; Δ -0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.68% (prev 45.48%; Δ 4.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 30.12 (EBITDA TTM 3.26b / Interest Expense TTM 90.4m) >= 6 (WARN >= 3)

Altman Z'' 8.13

(A) 0.35 = (Total Current Assets 8.75b - Total Current Liabilities 1.69b) / Total Assets 20.16b

(B) 0.38 = Retained Earnings (Balance) 7.61b / Total Assets 20.16b

(D) 3.44 = Book Value of Equity 7.61b / Total Liabilities 2.21b

Total Rating: 8.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.95

1. Piotroski 5.50pt = 0.50

2. FCF Yield 1.29% = 0.64

3. FCF Margin 21.81% = 5.45

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -1.04 = 2.50

6. ROIC - WACC (= 1.04)% = 1.30

7. RoE 15.57% = 1.30

8. Rev. Trend 96.85% = 7.26

9. EPS Trend -10.09% = -0.50

What is the price of ISRG shares?

As of October 20, 2025, the stock is trading at USD 446.13 with a total of 2,209,171 shares traded.
Over the past week, the price has changed by +2.39%, over one month by +1.69%, over three months by -13.56% and over the past year by -14.02%.

Is Intuitive Surgical a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Intuitive Surgical (NASDAQ:ISRG) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 70.95 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ISRG is around 414.30 USD . This means that ISRG is currently overvalued and has a potential downside of -7.13%.

Is ISRG a buy, sell or hold?

Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.

Strong Buy: 14
Buy: 8
Hold: 10
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the ISRG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	568.4	27.4%
Analysts Target Price	568.4	27.4%
ValueRay Target Price	476.2	6.7%

Last update: 2025-10-19 02:01

ISRG Fundamental Data Overview

Market Cap USD = 159.93b (159.93b USD * 1.0 USD.USD)
P/E Trailing = 62.1351
P/E Forward = 47.8469
P/S = 17.4879
P/B = 8.899
P/EG = 2.7875
Beta = 1.611
Revenue TTM = 9.14b USD
EBIT TTM = 2.72b USD
EBITDA TTM = 3.26b USD
Long Term Debt = unknown (none)
Short Term Debt = 33.5m USD (from shortTermDebt, last fiscal year)
Debt = 146.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -3.40b USD (from netDebt column, last quarter)
Enterprise Value = 154.75b USD (159.93b + Debt 146.0m - CCE 5.33b)
Interest Coverage Ratio = 30.12 (Ebit TTM 2.72b / Interest Expense TTM 90.4m)
FCF Yield = 1.29% (FCF TTM 1.99b / Enterprise Value 154.75b)
FCF Margin = 21.81% (FCF TTM 1.99b / Revenue TTM 9.14b)
Net Margin = 28.51% (Net Income TTM 2.61b / Revenue TTM 9.14b)
Gross Margin = 66.65% ((Revenue TTM 9.14b - Cost of Revenue TTM 3.05b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 64.69%)
Tobins Q-Ratio = 7.67 (Enterprise Value 154.75b / Total Assets 20.16b)
Interest Expense / Debt = 61.92% (Interest Expense 90.4m / Debt 146.0m)
Taxrate = 20.18% (167.9m / 832.1m)
NOPAT = 2.17b (EBIT 2.72b * (1 - 20.18%))
Current Ratio = 5.17 (Total Current Assets 8.75b / Total Current Liabilities 1.69b)
Debt / Equity = 0.01 (Debt 146.0m / totalStockholderEquity, last quarter 17.85b)
Debt / EBITDA = -1.04 (Net Debt -3.40b / EBITDA 3.26b)
Debt / FCF = -1.71 (Net Debt -3.40b / FCF TTM 1.99b)
Total Stockholder Equity = 16.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.93% (Net Income 2.61b / Total Assets 20.16b)
RoE = 15.57% (Net Income TTM 2.61b / Total Stockholder Equity 16.74b)
RoCE = 14.74% (EBIT 2.72b / Capital Employed (Total Assets 20.16b - Current Liab 1.69b))
RoIC = 12.98% (NOPAT 2.17b / Invested Capital 16.74b)
WACC = 11.94% (E(159.93b)/V(160.07b) * Re(11.95%) + (debt cost/tax rate unavailable))
Discount Rate = 11.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 59.75% ; FCFE base≈1.36b ; Y1≈1.07b ; Y5≈691.6m
Fair Price DCF = 21.13 (DCF Value 7.58b / Shares Outstanding 358.5m; 5y FCF grow -26.02% → 3.0% )
EPS Correlation: -10.09 | EPS CAGR: -54.90% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.85 | Revenue CAGR: 17.73% | SUE: 1.53 | # QB: 4

Additional Sources for ISRG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle